These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2787049)

  • 41. [Skeletal distribution and biological markers of Paget's disease].
    Meunier PJ; Salson C; Delmas PD
    Rev Prat; 1989 Apr; 39(13):1125-8. PubMed ID: 2786643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism.
    Minisola S; Scarnecchia L; Carnevale V; Bigi F; Romagnoli E; Pacitti MT; Rosso R; Mazzuoli GF
    J Endocrinol Invest; 1989 Sep; 12(8):537-42. PubMed ID: 2592739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two-site enzyme immunoassay for measuring intact human osteocalcin in serum.
    Parviainen M; Kuronen I; Kokko H; Lakaniemi M; Savolainen K; Mononen I
    J Bone Miner Res; 1994 Mar; 9(3):347-54. PubMed ID: 8191928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum osteocalcin levels in normal subjects and patients with primary hyperparathyroidism.
    Ljunghall S; Hällgren R; Rastad J
    Exp Clin Endocrinol; 1985 Dec; 86(2):218-22. PubMed ID: 3879222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.
    Slovik DM; Gundberg CM; Neer RM; Lian JB
    J Clin Endocrinol Metab; 1984 Aug; 59(2):228-30. PubMed ID: 6610686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease.
    Seibel MJ; Woitge HW; Pecherstorfer M; Karmatschek M; Horn E; Ludwig H; Armbruster FP; Ziegler R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3289-94. PubMed ID: 8784085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum osteocalcin radioimmunoassay in bone diseases.
    Galli M; Nuti R; Franci B; Righi G; Martorelli MT; Turchetti V; Caniggia M
    Ric Clin Lab; 1985; 15(3):253-7. PubMed ID: 3878567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of primary hyperparathyroidism in the follow-up of a patient with Paget's disease].
    Spivacow FR
    Medicina (B Aires); 2009; 69(1 Pt 2):173-6. PubMed ID: 19414302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isotope retention for assessment of bone turnover in involutional osteoporosis.
    Passeri M; Palummeri E; Baroni MC; Quaini F; Quintavalla A; Barbagallo M; Franchini D; Ugolotti D
    Clin Rheumatol; 1989 Jun; 8 Suppl 2():35-40. PubMed ID: 2788063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasmatic markers of bone metabolism.
    Tamburino G; Fiore CE
    Ann Ital Med Int; 1990; 5(3 Pt 3):296-302. PubMed ID: 2081090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in plasma bone GLA protein during treatment of bone disease.
    Deftos LJ; Parthemore JG; Price PA
    Calcif Tissue Int; 1982 Mar; 34(2):121-4. PubMed ID: 6805917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between bone uptake of 99mTc-pyrophosphate and hydroxyproline in blood and urine.
    Wiegmann T; Kirsh J; Rosenthall L; Kaye M
    J Nucl Med; 1976 Aug; 17(8):711-4. PubMed ID: 180269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dosage of ionized calcium in osteo-articular pathology].
    Eisinger J; Schiano A
    Rev Rhum Mal Osteoartic; 1978 Jun; 45(6):423-9. PubMed ID: 684354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Nephrolithiasis and bone involvement in primary hyperparathyroidism. The relative role of vitamin D].
    Díez Labajo A; Traba ML; Rapado A; Alvarez Arroyo MV; Peramo B; Díaz Curiel M; de la Piedra C; Calleja JL
    Rev Clin Esp; 1992 Mar; 190(5):238-42. PubMed ID: 1579694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD).
    Ryan PJ; Sherry M; Gibson T; Fogelman I
    Br J Rheumatol; 1992 Feb; 31(2):97-101. PubMed ID: 1371084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-partum hypercalcemia in hereditary hyperphosphatasia (juvenile Paget's disease).
    Chosich N; Long F; Wong R; Topliss DJ; Stockigt JR
    J Endocrinol Invest; 1991; 14(7):591-7. PubMed ID: 1940065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary excretion of glycosaminoglycans and hydroxyproline in Paget's disease of bone, compared with neoplastic invasion of bone.
    Bower L; Manley G
    J Clin Pathol; 1981 Oct; 34(10):1097-101. PubMed ID: 7309892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease.
    Duda RJ; O'Brien JF; Katzmann JA; Peterson JM; Mann KG; Riggs BL
    J Clin Endocrinol Metab; 1988 May; 66(5):951-7. PubMed ID: 3258870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
    Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
    Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.